Moderna sees higher COVID vaccine sales later this year
Reuters
Published May 04, 2022 07:04AM ET
Updated May 04, 2022 10:20AM ET
By Manas Mishra
(Reuters) -Moderna Inc on Wednesday forecast higher vaccine sales for the second half of the year than in the first six months, as it expects the virus that causes COVID-19 to follow a more seasonal pattern requiring booster shots in the fall.
The U.S. vaccine maker is developing a potential next generation booster targeted at both the Omicron variant as well as the original strain of the coronavirus in hopes of producing broader protection.
"The desired features for a northern hemisphere fall winter booster we think will be that it improves the durability of neutralizing antibodies against Omicron," said Moderna (NASDAQ:MRNA) President Stephen Hoge.
Hoge expects annual boosters to be needed for people at high-risk of severe illness, which Moderna estimates consists of roughly 1.7 billion people worldwide.
Moderna forecast $21 billion in 2022 COVID-19 vaccine sales but cautioned that it could be lower if the COVAX international vaccine-sharing program is unable to confirm demand for the shots from low- to middle-income countries.
Chief Financial Officer David Meline, however, said sales could be higher if the United States and other countries decided to sign contracts for a fall booster dose.
Pfizer (NYSE:PFE) on Tuesday maintained its 2022 forecast of $32 billion for sales if its rival COVID vaccine developed with BioNTech after raising it every quarter last year, a sign that dizzying growth has slowed.
Sales of Moderna's vaccine - its lone commercial product - rose to $5.9 billion in the first quarter from $1.7 billion a year ago. Total sales of $6.1 billion beat estimates of $4.62 billion, according to IBES data from Refinitiv.
The results and forecast appeared to ease some worries about vaccine sales this year, as Moderna shares rose more than 6% in pre-market trading. But they turned negative and were down around 1% in line with the broader Nasdaq.
Moderna delivered an exceptionally strong first quarter, said Lee Brown at research firm Third Bridge.
But future vaccine sales remain uncertain as countries relax pandemic curbs, cases fluctuate, and the demand for annual boosters has yet to be determined.
Get The News You Want
"Of course, the focus is less on 2022," Brown said, "and remains on Moderna’s future, when revenue is expected to plummet."
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.